Enveric Biosciences Announces Participation in 2026 BIO International Convention
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that the company is participating in the BIO International Convention being held June 22-25, 2026, in San Diego, California.
“We are arriving at BIO with strong operational momentum, driven by the recently announced positive preclinical phototoxicity results and the initiation of IND-enabling GLP genotoxicity studies for EB-003,” said Joseph Tucker, Ph.D., CEO of Enveric Biosciences. “This milestone moves us steadily toward IND submission and Phase 1 clinical entry. We are looking forward to meeting with potential strategic partners at the convention to discuss our continued progress and the unique mechanism of EB-003.”
Members of the Enveric management team will host meetings throughout the convention. Registered attendees can request a meeting using the BIO One-on-One PartneringTM platform.
About Enveric Biosciences
